Meet Alex Grassin

Fractional CFO and strategic finance support to early-stage Biotech and Medtech companies, advising on fundraising, M&A, cross-border operations, and financial infrastructure for clients including Aleva Neurotherapeutics, HiFiBiO Therapeutics, and Elos Medtech.

Global clinical-stage biotech company with operations in the US, France and China, advancing antibody therapies for cancer and autoimmune diseases, with three ongoing Phase 1 trials and two out-licensed assets to Fibrogen. ❖ Led international recruitment and development of a high-performing global finance team ❖ Consolidated all accounting and financial operations under the US headquarters, enhancing efficiency and alignment ❖ Directed finance IPO readiness efforts and spearheaded investor outreach initiatives

Clinical-stage biotech company with operations in the US and Canada, developing non-viral gene therapies for mucosal and systemic diseases. Its lead candidate, EG-70, targets non-muscle invasive bladder cancer (NMIBC). ❖ Played a key role in the business combination between enGene Inc and Forbion European Acquisition Corp (FEAC) a listed company on Nasdaq (SPAC Transaction for a total of $135M including PIPE investment, other private investment, and non-redemption commitments)

Swiss commercial-stage MedTech company with operations in Switzerland and in Germany, developing deep brain stimulation (DBS) devices for neurological disorders like Parkinson’s disease. ❖ Partnered with the CEO to lead the company's transformation from R&D to commercialization. ❖ Closed two private funding rounds totalling of $19M. ❖ Negotiated licensing deals and joint ventures in Europe and China

Clinical-stage biotech company (Phase 2) with operations in Switzerland and France, developing NOX enzyme inhibitors for fibrotic diseases including primary biliary cholangitis (PBC). ❖ Executed $87M sale to Calliditas via a block trade sale, followed by a mandatory tender offer. ❖ Led the strategic reverse takeover (RTO) with Genticel, achieving public listing on Euronext. ❖ Closed three private rounds, raising a total of $61M, with funds distributed across two countries. ❖ Secured a $9M convertible loan with warrants attached. ❖ Completed a public fundraising of $5M with preferential shareholders' subscription rights.

Alexion Pharmaceuticals, a rare disease-focused biotech now part of AstraZeneca, develops innovative therapies for ultra-rare conditions such as PNH and aHUS, most notably through its complement-inhibitor drugs Soliris and Ultomiris.

Novartis Consumer Health was the over-the-counter division of Novartis, offering products like Excedrin, Voltaren, and Lamisil, before being merged into a joint venture with GSK and ultimately becoming part of Haleon, a global consumer health company focused on self-care and wellness.

Intrawest Europe was focused on developing and operating upscale, village-style ski-resort real estate projects in the French Alps—such as Arc 1950 (Les Arcs) and Flaine Montsoleil—bringing Intrawest’s North American “four‑season village” model to Europe

KPMG Audit in Paris is the Paris-based entity of the global Big Four professional services network, providing statutory audit, assurance, accounting, tax, and advisory services—leveraging both local expertise and international affiliation to serve a broad range of clients